Complement component 3

TraceyBryantStuckey.com Congratulates all of the National Board Certified Teachers on Score Release Day

Retrieved on: 
Saturday, December 10, 2022
National Board for Professional Teaching Standards, CSP, Education, Learning, Architecture, Complement component 3, PGE v. Bureau of Labor and Industries, Initial, Classroom, Component, Confetti, Growth, Student, MOC, Medicine, Tutoring, Certification

TraceyBryantStuckey.com would like to say "Congratulations on this significant accomplishment that makes you shine as one of the best teachers in our nation!"

Key Points: 
  • TraceyBryantStuckey.com would like to say "Congratulations on this significant accomplishment that makes you shine as one of the best teachers in our nation!"
  • Candidates complete a series of rigorous components that culminate in a portfolio scored at the national level ensuring the highest level of authenticity.
  • This can be a day of celebration for those achieving or maintaining certification, however this day is also somber for those who do not achieve.
  • For the most current and up to date offerings, be sure to visit current offerings for teachers at www.traceybryantstuckey.com .

CUPE 4163 and University of Victoria reach tentative agreement

Retrieved on: 
Tuesday, November 29, 2022
Public Policy, Government, Labor, Other Policy Issues, Complement component 3, Public, UVIC, CUPE, University of Victoria, University, Music

The University of Victoria Educational Workers Union (CUPE 4163) Component 3 has reached a tentative agreement with UVic.

Key Points: 
  • The University of Victoria Educational Workers Union (CUPE 4163) Component 3 has reached a tentative agreement with UVic.
  • I want to thank the members of CUPE 4163 Component 3 for their support during this round of bargaining.
  • Further details on the agreement wont be released until presented to CUPE 4163 Component 3 members and a ratification vote it is held next week.
  • CUPE 4163 Component 3 is one of three components represented by the Canadian Union of Public Employees Local 4163 at the University of Victoria, with over 1500 members.

Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy

Retrieved on: 
Wednesday, March 10, 2021
Complement system, Alcohols, Complement component 3, C3b, Geographic atrophy, Ethylene glycol, Complement factor I

The analysis, Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan, was published in the American Journal of Ophthalmology , and showed that efficacy results across patient subgroups were consistent with the FILLY results.

Key Points: 
  • The analysis, Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan, was published in the American Journal of Ophthalmology , and showed that efficacy results across patient subgroups were consistent with the FILLY results.
  • Published in Ophthalmology , Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy, further clarified characteristics of investigator-determined exudations reported in the study.
  • These data from two new analyses of our positive Phase 2 FILLY study reinforce the potential of pegcetacoplan in GA, and we look forward to sharing results from our Phase 3 GA studies in the third quarter of this year.
  • Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b.

Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update

Retrieved on: 
Thursday, February 25, 2021
Branches of biology, Medicine, Health sciences, A2M, Biomarkers, alpha-2-Macroglobulin, Clinical trial, Cash and cash equivalents, Macroglobulin, Complement component 3

CY6463 administration resulted in improvement in the levels of various neuroinflammatory biomarkers, including alpha-2-macroglobulin (A2M) and Complement C3 (C3).

Key Points: 
  • CY6463 administration resulted in improvement in the levels of various neuroinflammatory biomarkers, including alpha-2-macroglobulin (A2M) and Complement C3 (C3).
  • ADv Clinical Trial Initiation: The Company anticipates initiating a 12-week Phase 2a clinical trial in patients with ADv midyear.
  • Cash Position:Cash, cash equivalents, and restricted cash balance onDecember 31, 2020 was approximately$58 million, as compared toapproximately$71milliononSeptember 30, 2020.
  • For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn ( www.linkedin.com/company/cyclerion ).

NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition

Retrieved on: 
Tuesday, February 9, 2021
Medical specialties, Branches of biology, Immune system, Choroidal neovascularization, Ophthalmology, Complement system, Complement component 3, Lectin, CNV

In preclinical models, NGM621s high affinity binding to C3 has demonstrated the potential for potent C3 inhibition.

Key Points: 
  • In preclinical models, NGM621s high affinity binding to C3 has demonstrated the potential for potent C3 inhibition.
  • Preclinical data also suggest that NGM621 may not exacerbate choroidal neovascularization (CNV); the human translation of this observation is being investigated in the ongoing CATALINA Phase 2 clinical trial.
  • C3 is a key component of the complement system, which helps orchestrate the bodys response to infection and maintains tissue homeostasis.
  • The complement cascade can be activated through its three distinct pathways classical, lectin and alternative all of which converge to activate C3.

Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer  

Retrieved on: 
Wednesday, January 6, 2021
Companies, Health care, Health sciences, Mallinckrodt, AstraZeneca, Pharmaceutical industry in China, Complement component 3, Forward-looking statement, Complement system

Silence is also developing SLN500, a C3 targeting program in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases.

Key Points: 
  • Silence is also developing SLN500, a C3 targeting program in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases.
  • Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda.
  • Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

Innovative Digital Culinary Platform C3 Solidifies Explosive Growth as CEO and Founder Sam Nazarian Hires 20 Additional Senior Team Members and Industry Veterans

Retrieved on: 
Wednesday, December 2, 2020
Complement system, Complement component 3

More importantly, the company is acting on a pillar of job creation with the addition of 20 members to the C3 team.

Key Points: 
  • More importantly, the company is acting on a pillar of job creation with the addition of 20 members to the C3 team.
  • New team members include two executive leadership positions meant to help oversee the company's strategic growth.
  • Thomas Negrel, who joins C3 as Senior Vice President of Finance and Strategy, will focus on accelerating the acquisition of new venues for C3 digital kitchens and use of C3 technology.
  • C3 (Creating Culinary Communities) is re-imagining the food service industry at a time when change is needed most.

NGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at American Academy of Ophthalmology (AAO) 2020 Virtual

Retrieved on: 
Thursday, November 5, 2020
Medical specialties, Complement system, Clinical medicine, Medicine, Immune system, Complement component 3, Intravitreal administration, Lectin

The presentation will include detailed first-in-human safety, tolerability and pharmacokinetics (PK) findings from single and multiple intravitreal injections of NGM621 in patients with geographic atrophy (GA).

Key Points: 
  • The presentation will include detailed first-in-human safety, tolerability and pharmacokinetics (PK) findings from single and multiple intravitreal injections of NGM621 in patients with geographic atrophy (GA).
  • In preclinical models, NGM621s high affinity binding to C3 has demonstrated the potential for potent C3 inhibition.
  • C3 is a key component of the complement system, which helps orchestrate the bodys response to infection and maintains tissue homeostasis.
  • The complement cascade can be activated through its three distinct pathways classical, lectin and alternative all of which converge to activate C3.

Silence Therapeutics Appoints Dr. Marie Wikström Lindholm to its Executive Leadership Team

Retrieved on: 
Monday, November 2, 2020
Companies, Health care, Mallinckrodt, AstraZeneca, Articles, Pharmaceutical industry in China, Complement component 3, Forward-looking statement, Complement system, Complement factor I

Silence is also developing SLN500, a C3 targeting programme, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases.

Key Points: 
  • Silence is also developing SLN500, a C3 targeting programme, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases.
  • Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda.
  • Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity

Retrieved on: 
Thursday, October 15, 2020
Medical specialties, Clinical medicine, Medicine, C-reactive protein, C3a, Lactate dehydrogenase, Complement component 3, Complement system, Complement membrane attack complex, Interleukin 6, C4A, Complement component 4

CRP, C-reactive protein; IL-6, interleukin 6; LDH, lactate dehydrogenase; TCC, terminal complement complex; ULN, upper limit of normal.

Key Points: 
  • CRP, C-reactive protein; IL-6, interleukin 6; LDH, lactate dehydrogenase; TCC, terminal complement complex; ULN, upper limit of normal.
  • Apellis also announced preliminary results from the first part of the interventional Phase 1/2 study of APL-9 in patients with severe COVID-19.
  • The observational exploratory study evaluated the relationship between markers of complement activation and disease severity in 41 patients with COVID-19.
  • The primary objective of the observational study was to quantify systemic concentrations of the complement activation products Bb, C3a, C4a and terminal complement complex (TCC) and correlate them to COVID-19 severity.